Alembic Pharmaceuticals Q2 Results FY27: Net Profit Jumps 121.62% to Rs 409.36 Cr, Revenue Rs 2,391.65 Cr
- November 4, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Alembic Pharmaceuticals Q2 Results FY27 were declared on 4 November 2026. Revenue rose 25.21% YoY to Rs 2,391.65 Cr from Rs 1,910.15 Cr, and net profit rose 121.62% YoY to Rs 409.36 Cr from Rs 184.71 Cr. These quarterly results show YoY growth on both lines, with profit growing faster than revenue.
Alembic Pharmaceuticals Ltd (APLLTD) Q2 Results FY27 announced on 4 November 2026, covering the company’s financial performance for the July to September quarter. Revenue stood at Rs 2,391.65 Cr and PAT at Rs 409.36 Cr. This note on Alembic Pharmaceuticals Q2 Results FY27 compares both figures with the same quarter a year earlier, and the results date anchors that comparison to the latest filing. Together, these two figures set the scale of the quarter and frame the sections that follow.
This results analysis of Alembic Pharmaceuticals Q2 Results covers the financial highlights, the business drivers, the outlook and the risks in sequence. The Financial Highlights table that comes next sets each metric of the quarter against the year-ago quarter.
Click Here – Get Free Investment Predictions
Alembic Pharmaceuticals Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 2391.65 Cr | Rs 1910.15 Cr | +25.21% YoY |
| Net Profit (PAT) | Rs 409.36 Cr | Rs 184.71 Cr | +121.62% YoY |
Source: company filing for Alembic Pharmaceuticals Q2 Results FY27, 4 November 2026. Figures in Rs Crore.
Key Takeaways from Alembic Pharmaceuticals Q2 Results: What Stands Out
- Revenue of Rs 2,391.65 Cr rose 25.21% YoY from Rs 1,910.15 Cr, which is the YoY growth recorded on the top line.
- Net profit of Rs 409.36 Cr rose 121.62% YoY from Rs 184.71 Cr, more than double the year-ago figure in Alembic Pharmaceuticals Q2 Results FY27.
- Net profit margin of 17.1% improved from 9.7% in the comparison quarter as net profit grew faster than revenue.
- Quarterly net profit has been volatile, ranging from Rs 132.97 Cr to Rs 409.36 Cr over the last 5 quarters.
- The performance analysis below sets these revenue and net profit figures side by side.
Alembic Pharmaceuticals Q2 Results FY27: Performance Analysis
Both revenue and profit rose, with profit rising faster. Alembic Pharmaceuticals earned revenue of Rs 2,391.65 Cr against Rs 1,910.15 Cr in the same quarter last year, and net profit reached Rs 409.36 Cr against Rs 184.71 Cr. The size of the gap between the two rates of change is the main feature of the quarter.
In Alembic Pharmaceuticals Q2 Results FY27, net profit grew 121.62% YoY while revenue grew 25.21% YoY, so net profit margin moved from 9.7% to 17.1%. The quarterly results therefore show profit expanding at roughly five times the pace of revenue.
The Alembic Pharmaceuticals Q2 Results figures give investors a fixed base for later filings, and Univest Screener users can follow the same metrics across periods. This results analysis treats Alembic Pharmaceuticals Q2 Results FY27 as the reference quarter and now turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis starts with revenue, which grew 25.2% year on year to Rs 2,391.65 Cr in the latest quarter, lifting the top line well above the Rs 1,910.15 Cr of a year earlier.
Net Profit Growth – Net profit rose 121.6% year on year to Rs 409.36 Cr, and Alembic Pharmaceuticals Q2 Results FY27 show this as the larger of the two movements, since the profit line more than doubled while revenue rose by about a quarter.
Net Profit Margin – Net profit margin improved to 17.1% from 9.7% in the comparison quarter, so each rupee of revenue carried more net profit, as the quarterly results confirm.
FY27 Outlook After Alembic Pharmaceuticals Q2 Results
FY27 full-year results will depend on the quarters still to be reported and on the conditions the company discloses. After Alembic Pharmaceuticals Q2 Results FY27, revenue of Rs 2,391.65 Cr and net profit of Rs 409.36 Cr give the base against which later quarters will be read. Because the outlook rests only on filed figures, readers should treat later disclosures as the next checkpoints.
This results analysis stays within the reported numbers and does not project beyond them. Later filings will show how net profit moves within the range seen over the last 5 quarters, and Univest app users can follow those filings as they arrive. The risks below set out what to watch.
Key Risks to Watch After Alembic Pharmaceuticals Q2 Results FY27
Volatile Quarterly Profit
Quarterly net profit has been volatile, ranging from Rs 132.97 Cr to Rs 409.36 Cr over the last 5 quarters. Investors following Alembic Pharmaceuticals Q2 Results FY27 can check where later filings sit within that range.
Lower Return on Capital
Return on capital employed declined to 11.74% in FY26 from 13.51% in FY25. This annual decline contrasts with the YoY growth in quarterly profit and is worth tracking in later filings.
Return on Equity Below 15%
Return on equity of 12.35% in FY26 is below 15%. This is an annual measure, so it frames the longer-term profitability picture against which the latest quarter can be read. Readers can compare this with the quarterly improvement to see how the two measures differ.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Alembic Pharmaceuticals Q2 Results FY27 show revenue of Rs 2,391.65 Cr and net profit of Rs 409.36 Cr, both higher than a year earlier. Revenue grew 25.21% YoY and net profit grew 121.62% YoY, which is the central result of the quarter. The quarterly results give a clear base for comparing the next filings. A full read of Alembic Pharmaceuticals Q2 Results supports that comparison, and investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Alembic Pharmaceuticals Q2 Results FY27
What are Alembic Pharmaceuticals Q2 Results FY27?
Ans. Alembic Pharmaceuticals Q2 Results FY27 are the quarterly results for July to September 2026, with revenue of Rs 2,391.65 Cr and net profit of Rs 409.36 Cr, as the Quick Answer box shows.
What is the results date for Alembic Pharmaceuticals Q2 Results FY27?
Ans. The results date for Alembic Pharmaceuticals Q2 Results FY27 is 4 November 2026, so the YoY comparison uses the same quarter a year earlier, as the opening paragraphs explain.
What revenue was reported in Alembic Pharmaceuticals Q2 Results FY27?
Ans. Alembic Pharmaceuticals reported revenue of Rs 2,391.65 Cr in Q2 FY27 against Rs 1,910.15 Cr a year earlier, which means the Financial Highlights table shows a rise of 25.21%.
What net profit was reported in Alembic Pharmaceuticals Q2 Results FY27?
Ans. Net profit in Q2 FY27 was Rs 409.36 Cr against Rs 184.71 Cr in the same quarter last year, so the Key Takeaways section records a rise of 121.62% YoY.
How much YoY growth did revenue show in Alembic Pharmaceuticals Q2 Results FY27?
Ans. Alembic Pharmaceuticals Q2 Results FY27 show revenue up 25.21% YoY, from Rs 1,910.15 Cr to Rs 2,391.65 Cr, while the Performance Analysis section notes that net profit grew by a larger 121.62%.
Did net profit rise or fall in Alembic Pharmaceuticals Q2 Results?
Ans. Alembic Pharmaceuticals Q2 Results show net profit rising 121.62% YoY to Rs 409.36 Cr, which means the Performance Analysis section describes profit as growing faster than revenue.
What was the net profit margin in Alembic Pharmaceuticals Q2 Results FY27?
Ans. Net profit margin in Q2 FY27 was 17.1% against 9.7% in the comparison quarter, so each rupee of revenue carried more net profit, as the Key Business Factors section notes.
How much YoY growth did net profit show in Alembic Pharmaceuticals Q2 Results FY27?
Ans. Net profit grew 121.62% YoY in Alembic Pharmaceuticals Q2 Results FY27, more than doubling from Rs 184.71 Cr to Rs 409.36 Cr, while revenue grew 25.21% over the same period, as the Key Takeaways section shows.
What business factors shaped Alembic Pharmaceuticals Q2 Results FY27?
Ans. Revenue growth of 25.2%, net profit growth of 121.6% and a net profit margin that improved to 17.1% shaped the quarter, as the Key Business Factors section details.
What are the key risks after Alembic Pharmaceuticals Q2 Results FY27?
Ans. The listed risks are volatile quarterly net profit, a return on capital employed that fell to 11.74% in FY26 and a return on equity of 12.35% below 15%, covered in the Key Risks section.
What is the outlook after Alembic Pharmaceuticals Q2 Results?
Ans. FY27 full-year results will depend on the quarters still to be reported, while the Rs 2,391.65 Cr revenue and Rs 409.36 Cr net profit act as the base, as the Outlook section explains.
Where can I find the complete Alembic Pharmaceuticals Q2 Results FY27 data?
Ans. The Financial Highlights table in this article lists the quarter’s metrics against the same quarter last year, and the Univest Screener lets investors follow these figures over time.
